Pharmaceutical Chemistry Journal

, Volume 27, Issue 7, pp 453–463 | Cite as

Pharmacological properties and mechanisms of action of new antidepressants (review)

  • N. I. Andreeva
Molecular-Biological Problems in the Creation of Therapeutic Agents and Studies of their Mechanisms of Action


Organic Chemistry Pharmacological Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature cited

  1. 1.
    G. Ya. Avrutskii and O. P. Vertogradova, New Therapeutic Agents, Ékspress-inform., No. 1, 9–20 (1973).Google Scholar
  2. 2.
    N. I. Andreeva, R. G. Glushkov, and M. D. Mashkovskii, Khim.-farm. Zh., No. 4, 111–114 (1979).Google Scholar
  3. 3.
    A Handbook of the Scientific Studies of the Science Research Institute of Pharmacology [in Russian], A. V. Vel'dman (ed.), Moscow (1990).Google Scholar
  4. 4.
    I. P. Lapin, Antidepressants and Nootropic Agents [in Russian], Leningrad (1982), pp. 88–101.Google Scholar
  5. 5.
    M. D. Mashkovskii, A. N. Grinev, and N. I. Andreeva, Khim.-farm. Zh., No. 3, 60–63 (1974).Google Scholar
  6. 6.
    G. P. Panteleeva, B. S. Belyaev, K. E. Borisova, et al., Antidepressants and Nootropic Agents [in Russian], Leningrad (1982), pp. 42–48.Google Scholar
  7. 7.
    V. N. Sinyukhin, The Metabolism of the New Antidepressant Azafen and its Effects on Noradrenaline Metabolism [in Russian], Author's abstract of dissertation for Doctorate in Medical Sciences, Moscow (1974).Google Scholar
  8. 8.
    V. I. Fedortsov and A. N. Zavarzina, New Therapeutic Agents. Éksp.-inform., No. 8, 18–23 (1982).Google Scholar
  9. 9.
    M. A. Blackshear, L. R. Steranka, and E. Sanders-Buch, Eur. J. Pharmacol.,76, 325–328 (1981).Google Scholar
  10. 10.
    R. N. Brogden, et al., Drugs,18, 1–24 (1979).Google Scholar
  11. 11.
    R. N. Brogden, et al., Drugs,21, 401–429 (1981).Google Scholar
  12. 12.
    E. A. Burch, Jr. and J. H. Downs, J. Clin. Psychopharmacol.,7, 55–56 (1987).Google Scholar
  13. 13.
    G. D. Burrows, et al., (eds.), Antidepressant Drugs in Psychiatry, Amsterdam-New York-Oxford (1983), Vol. 1.Google Scholar
  14. 14.
    J. Castaner and S. S. Chatterjee, Drugs Future,1, 551–554 (1976).Google Scholar
  15. 15.
    L. A. Chiodo and S. M. Antelman, Eur. J. Pharmacol.,66, 255–256 (1980).Google Scholar
  16. 16.
    V. Claasen, et al., Br. J. Pharmacol.,60, 505–516 (1977).Google Scholar
  17. 17.
    A. Coppen, et al., Psychopharmacology,63, 199–202 (1979).Google Scholar
  18. 18.
    R. A. Dominguez, et al., J. Clin, Psychiatr.,46, 84–87 (1985).Google Scholar
  19. 19.
    P. T. Donlon, H. Biertuemphez, and M. Willenbring, J. Clin. Psychiatr.,42, 11–15 (1981).Google Scholar
  20. 20.
    R. S. Ehsanuellah, et al., Psychopharmacology,52, 73–77 (1977).Google Scholar
  21. 21.
    Ch. J. Fowler, Drugs Future,7, 501–517 (1982).Google Scholar
  22. 22.
    R. W. Fuller, H. D. Snoddy, and K. W. Perry, Neuropharmacology,18, 767–770 (1979).Google Scholar
  23. 23.
    K. Fuxe, S. O. Orgen, L. G. Agnati, et al., Neuropharmacology,22, 389–400 (1983).Google Scholar
  24. 24.
    K. Fuxe, et al., Typical and Atypical Antidepressants, New York (1982), pp. 91–107.Google Scholar
  25. 25.
    M. Grau, Drugs Future,8, 124–126 (1983).Google Scholar
  26. 26.
    H. Hall and S. O. Orgen, Eur. J. Pharmacol.,70, 393–407 (1981).Google Scholar
  27. 27.
    A. Yanowsky, et al., Science,218, 900–901 (1982).Google Scholar
  28. 28.
    J. F. Ancher, Med. Actual/Drugs Today,20, 417–422 (1984).Google Scholar
  29. 29.
    S. Lipper, et al., Psychopharmacology,62, 123–128 (1979).Google Scholar
  30. 30.
    A. Moretti, et al., Biochem. Pharmacol.,30, 2728–2731 (1981).Google Scholar
  31. 31.
    S. O. Orgel, S. Ross, H. Hall, and T. Archer, Antidepressants, G. D. Burrows, et al. (eds.), Amsterdam-New York-Oxford (1983), pp. 13–34.Google Scholar
  32. 32.
    M. Peet and H. Behagel, B. J. Clin. Pharmacol.,5, Suppl. 1, 5–9 (1978).Google Scholar
  33. 33.
    R. M. Pinder, et al., Drugs,13, 321–352 (1977).Google Scholar
  34. 34.
    R. M. Pinder, et al., Drugs,13, 401–421 (1977).Google Scholar
  35. 35.
    C. P. Robinson, Drugs Today,24, 7–13 (1988).Google Scholar
  36. 36.
    M. V. Rudorfer and W. Z. Potter, Drugs,37, 713–738 (1989).Google Scholar
  37. 37.
    A. F. Schatzeberg, et al., J. Clin. Psychopharmacol.,7, 44S-49S (1987).Google Scholar
  38. 38.
    W. C. Stern and N. Harto-Truax, Psychopharmacol. Bull.,16, 43–46 (1980).Google Scholar
  39. 39.
    M. F. Sugrue, Biochem. Pharmacol.,32, 1811–1817 (1983).Google Scholar
  40. 40.
    F. Sulser, J. Vetulani, and P. Mobley, Biochem. Pharmacol.,27, 257–261 (1978).Google Scholar
  41. 41.
    P. Waldmeier and W. Schilling, Drugs Future,10, 371–373 (1985).Google Scholar
  42. 42.
    K. A. Wesnes, et al., Brit. J. Clin. Pharmacol.,27, 647P-648P (1989).Google Scholar
  43. 43.
    P. Willner, Psychopharmacology,85, 387–404 (1985).Google Scholar
  44. 44.
    M. B. H. Youdim, M. Da Prada, and R. Emrein (eds.), J. Neural. Transmission. Supplement 26 (1988).Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • N. I. Andreeva
    • 1
  1. 1.TsKhLS. S. Ordzhonikidze All-Union Scientific-Pharmaceutical InstituteMoscow

Personalised recommendations